Omnipod maker Insulet (PODD) reported a robust earnings report in early August. The insulin pump stock has been on the move ever since.
Wednesday's pick for IBD 50 Growth Stocks To Watch is trying to extend a four-day win streak and sits in a buy zone. Insulet is tapping into a new market of more than 38 million people that may be potential users of its medical device.
The IBD 50 name meets the stringent criteria to be on the IBD Sector Leaders list and it was Tuesday's IBD Stock Of The Day. Insulet stock was also discussed on Wednesday's episode of IBD Live.
Insulet makes Omnipod insulin pumps for people with diabetes. The product is sold in 25 countries and has more than 500,000 users.
Insulet's device serves customers with Type 1 diabetes. The company is expanding its use to people with Type 2 diabetes. As of 2021, the Centers for Disease Control and Prevention estimated 1.7 million people aged 20 and older in the U.S. have Type 1 diabetes. That compares with more than 38 million Americans with Type 2 diabetes, although not all of those patients will need insulin treatment.
The wearable system is tubeless and requires no daily injections, and can be combined with continuous glucose monitors.
Its Omnipod 5 app provides pump wearers with insulin delivery data and blood glucose levels. The app is fully compatible with Apple (AAPL) iPhones and Android smartphones and uses a DexCom (DXCM) sensor to gather data.
Insulet stock ranks No. 1 out of 125 stocks in the Medical-Products group, which holds the 136th spot out of the 197 industry groups that Investor's Business Daily tracks.
The stock holds an IBD SMR Rating of "A," meaning it is in the top 20% of names in terms of sales growth, profit margins, and return on equity, or ROE. Its 24% ROE is above the desired 17% that IBD seeks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Insulet stock gapped up more than 9% in heavy volume on Aug. 7, and retook its 50-day moving average. The move came after the Omnipod maker reported second-quarter earnings and sales that handily beat estimates.
The stock broke out of an early-stage, skewed cup-with-handle base with a 322.80 buy point Monday. Shares are in the 5% buy zone up to 338.94, according to MarketSurge pattern recognition.
Its relative strength line is back on the rise after falling to a low in early August.
Mutual funds own a hardy 70% of shares, and have added Insulet stock for five straight quarters, according to IBD Stock Checkup.
Insulet has a quality that IBD seeks. It had accelerated earnings over the last two quarters and rising sales growth over the last three quarters.
Its second-quarter profit grew to $1.17 per share, or a healthy 113%, which followed a 67% jump in the first quarter.
The insulin pump maker's revenue growth ramped up to 33% in the second quarter, from 17% and 29% in the respective previous two quarters. Insulet expects third-quarter revenue growth in the range of 22% to 25%. It also raised its full-year sales growth guidance to between 24% and 27%.
Wall Street forecasts show profit growth slowing to 27%, then to an average of 16% over the following three quarters.
Analysts call for third-quarter revenue to climb 25% followed by two quarters of 22% increases.
Its annual profit growth ranged from 110% to 400% from 2021 through 2023, with 2024 rising a more modest 19%. Full-year 2025 earnings estimates now show 43% growth then 25% in 2026.
Its robust profit growth earned Insulet a best-possible 99 IBD Earnings Per Share Rating and it holds a 97 Composite Rating.
Follow Kimberley Koenig for more stock market news on X, the platform formerly known as Twitter, @IBD_KKoenig.
YOU MAY ALSO LIKE:
Discover Profitable Trades Each Day With MarketDiem. See How.
What To Do When Growth Stocks Backtrack To Test Buy Points
Learn How To Time The Market With IBD's ETF Market Strategy
Looking For Market Insights? Check Out Our Live Daily Segment | Stocks To Watch
Learn How To Buy Stocks | Stocks To Watch
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.